RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May11, 2017, RXi Pharmaceuticals Corporation reported its
results of operations for the quarter ended March31, 2017.A copy
of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K (the Report).
The information in this Item2.02 and attached as Exhibit 99.1
to this Report will not be treated as filed for the purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section.This information will not be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or
into another filing under the Exchange Act, unless that filing
expressly incorporates this information by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.1 | Press Release dated May11, 2017. |
***
2
About RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII)
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response. RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) Recent Trading Information
RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) closed its last trading session up +0.041 at 0.581 with 252,934 shares trading hands.